Lexicon Pharmaceuticals, Inc. SEC filings LXRX
Lexicon Pharmaceuticals, Inc. has 1,003 filings in SEC EDGAR's recent list, going back to Jan 8, 2010. Its latest annual report, Form ARS, was filed on Mar 16, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 5, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Mar 16, 2026 | — |
| DEF 14A | Proxy statement | Mar 16, 2026 | Mar 16, 2026 |
| PRE 14A | Preliminary proxy statement | Feb 17, 2026 | Feb 17, 2026 |
| DEFA14A | Additional proxy material | Apr 22, 2025 | — |
| DEF 14A | Proxy statement | Apr 22, 2025 | Apr 22, 2025 |
| PRE 14A | Preliminary proxy statement | Mar 25, 2025 | Mar 20, 2025 |
| DEFA14A | Additional proxy material | Mar 26, 2024 | — |
| DEF 14A | Proxy statement | Mar 26, 2024 | Mar 25, 2024 |
| PRE 14A | Preliminary proxy statement | Mar 11, 2024 | Mar 11, 2024 |
| DEFA14A | Additional proxy material | Mar 17, 2023 | — |
| DEF 14A | Proxy statement | Mar 17, 2023 | Mar 16, 2023 |
| DEF 14A | Proxy statement | Apr 8, 2022 | Apr 7, 2022 |
| DEFA14A | Additional proxy material | Apr 8, 2022 | — |
| PRE 14A | Preliminary proxy statement | Mar 11, 2022 | Mar 11, 2022 |
| DEFA14A | Additional proxy material | Mar 19, 2021 | — |
| DEF 14A | Proxy statement | Mar 19, 2021 | Mar 19, 2021 |
| PRE 14A | Preliminary proxy statement | Feb 19, 2021 | Feb 19, 2021 |
| DEFA14A | Additional proxy material | Apr 7, 2020 | — |
| DEFA14A | Additional proxy material | Mar 13, 2020 | — |
| DEF 14A | Proxy statement | Mar 13, 2020 | Mar 13, 2020 |
| DEFA14A | Additional proxy material | Mar 15, 2019 | — |
| DEF 14A | Proxy statement | Mar 15, 2019 | Dec 31, 2018 |
| PRE 14A | Preliminary proxy statement | Feb 15, 2019 | Dec 31, 2018 |
| DEFA14A | Additional proxy material | Mar 16, 2018 | — |
| DEF 14A | Proxy statement | Mar 16, 2018 | Mar 16, 2018 |
| DEFA14A | Additional proxy material | Mar 17, 2017 | — |
| DEF 14A | Proxy statement | Mar 17, 2017 | Mar 17, 2017 |
| PRE 14A | Preliminary proxy statement | Feb 15, 2017 | Feb 15, 2017 |
| DEF 14A | Proxy statement | Mar 18, 2016 | Apr 28, 2016 |
| DEFA14A | Additional proxy material | Mar 18, 2016 | — |
| DEF 14A | Proxy statement | Mar 13, 2015 | Mar 13, 2015 |
| DEFA14A | Additional proxy material | Mar 13, 2015 | — |
| PRE 14A | Preliminary proxy statement | Feb 20, 2015 | Feb 20, 2015 |
| DEF 14A | Proxy statement | Mar 14, 2014 | Mar 13, 2014 |
| DEFA14A | Additional proxy material | Mar 14, 2014 | — |
| DEFA14A | Additional proxy material | Mar 25, 2013 | — |
| DEF 14A | Proxy statement | Mar 25, 2013 | May 9, 2013 |
| DEFA14A | Additional proxy material | Mar 16, 2012 | — |
| DEF 14A | Proxy statement | Mar 16, 2012 | Mar 16, 2012 |
| PRE 14A | Preliminary proxy statement | Feb 24, 2012 | Feb 24, 2012 |
| DEFA14A | Additional proxy material | Mar 18, 2011 | — |
| DEF 14A | Proxy statement | Mar 18, 2011 | Mar 18, 2011 |
| DEFA14A | Additional proxy material | Mar 19, 2010 | — |
| DEF 14A | Proxy statement | Mar 19, 2010 | Mar 19, 2010 |
Showing 44 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- LXRX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- The Woodlands, TX
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1062822
- Former names
- LEXICON PHARMACEUTICALS, INC./DE (until Dec 5, 2014); LEXICON GENETICS INC/TX (until Apr 2, 2007)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.